Hengrui Medicine: Three innovative drugs including HRS-6209 have received clinical trial approval notification.

Hengrui Pharmaceuticals announced that the company and its subsidiaries Shandong Shengdi Pharmaceuticals and Guangdong Hengrui Pharmaceuticals recently received approval from the National Medical Products Administration to conduct clinical trials on HRS-6209 capsules, HRS-8080 tablets, and HRS-9813 capsules. Clinical trials will be conducted soon. Among them, HRS-6209 is a new selective CDK4 inhibitor intended for the treatment of advanced malignant solid tumors. It has entered Phase II clinical trials, with an accumulated research and development investment of approximately 158 million yuan. HRS-8080 is an oral estrogen receptor degrader that has entered Phase II/III clinical trials, with an accumulated research and development investment of approximately 313 million yuan. HRS-9813 is a Type 1 innovative drug developed by the company with an accumulated research and development investment of approximately 177 million yuan.